BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors

Despite the clinical benefit associated with gilteritinib in relapsed/refractory acute myeloid leukemia (AML), most patients eventually develop resistance through unknown mechanisms. To delineate the mechanistic basis of resistance to gilteritinib, we performed targeted sequencing and scRNASeq on pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Buelow, Daelynn R., Bhatnagar, Bhavana, Orwick, Shelley J., Jeon, Jae Yoon, Eisenmann, Eric D., Stromatt, Jack C., Pabla, Navjot Singh, Blachly, James S., Baker, Sharyn D., Blaser, Bradley W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631628/
https://www.ncbi.nlm.nih.gov/pubmed/35797240
http://dx.doi.org/10.1182/bloodadvances.2022007952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631628/
https://www.ncbi.nlm.nih.gov/pubmed/35797240
http://dx.doi.org/10.1182/bloodadvances.2022007952

Ejemplares similares